Kalohexis Adds Biotech Veteran Garry Menzel to Board — Kalohexis Inc.

Event summary

Kalohexis appoints Garry Menzel, Ph.D., to its Board of Directors on September 1, 2026.
Menzel brings over 30 years of global healthcare executive leadership, including roles at TCR² Therapeutics, Black Diamond Therapeutics, and DaVita HealthCare Partners.
Menzel currently serves as an Operating Partner at Global Healthcare Opportunities (GHO) Capital.
Kalohexis is a clinical-stage biotechnology company focused on metabolic diseases, including obesity and cancer cachexia.
Menzel highlights Kalohexis' potential to transform obesity treatment with 710GO, addressing limitations of current incretin-based therapies.

The big picture

Kalohexis' appointment of Garry Menzel underscores its strategic focus on leveraging the melanocortin system for metabolic disease care. Menzel's extensive experience in biotech leadership and investment banking brings valuable insights to Kalohexis as it navigates the competitive landscape of obesity and cancer cachexia treatments. His background in successful mergers and acquisitions, such as the sale of Regulus Therapeutics to Novartis for $1.7 billion, positions him to guide Kalohexis through potential strategic transactions and growth phases.

What we're watching

Strategic Direction: How Menzel's experience in leading biotech companies will shape Kalohexis' pipeline advancement and potential partnerships.
Market Positioning: Whether Kalohexis can differentiate 710GO in the competitive obesity treatment landscape, addressing incretin limitations.
Execution Risk: The pace at which Kalohexis can progress its melanocortin-based pipeline, particularly in the absence of FDA-approved treatments for cancer cachexia.